Last Updated: November 8, 2026

Details for New Drug Application (NDA): 209422

NDA 209422 describes CARFILZOMIB, which is a drug marketed by Apotex, Breckenridge, Dr Reddys, and MSN, and is included in five NDAs. Additional details are available on the CARFILZOMIB profile page.

The generic ingredient in CARFILZOMIB is carfilzomib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the carfilzomib profile page.

Summary for 209422

Tradename:	CARFILZOMIB
Applicant:	Dr Reddys
Ingredient:	carfilzomib
Patents:	0

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	POWDER;INTRAVENOUS			Strength	60MG/VIAL
Approval Date:	Sep 9, 2019	TE:	AP	RLD:	No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.